The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Global liver disease burdens and research trends: Analysis from a Chinese perspective
Abstract
Liver diseases affect millions of people worldwide. In most developed countries, the incidence of viral hepatitis is waning as a result of modern advances in disease prevention, diagnosis, and therapies. Expanded programmes for systematic immunisation against hepatitis B virus have also significantly brought down the number of new cases in many countries, including China. In contrast, with the improvement in living standards, the prevalence of metabolic liver diseases including non-alcoholic fatty liver disease and alcohol-related liver disease is set to rise, ultimately leading to more cases of end-stage liver diseases (liver failure, cirrhosis, and liver cancer). Over the past 30 years, visionary governments of major nations have provided strong incentives for basic/clinical research, vaccination programmes, and drug discovery and development in the field of hepatology. To get rid of her unflattering title as the "leader in liver diseases", China has also made a serious effort to initiate nationwide preventive measures for liver diseases, global partnerships, and mentoring programmes for young hepatologists. Instrumental to such progress is the continuous support of the National Natural Science Foundation of China (NSFC), which has helped hepatology to thrive in virtually all research directions within the country. In this article, we seek to provide stimulating glimpses into the evolving liver disease epidemiology, institutional research profiles, funding landscape, and drug development trends in China, with an attempt to compare her status and achievements with those of the United States, European countries, and Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Prevalence and Control of Diabetes in Chinese Adults
Xu, Y. (2013) · JAMA · doi:10.1001/jama.2013.168118 · Cited by 2,703
Self-citationThe global burden of liver disease: The major impact of China
Wang, F., Fan, J., Zhang, Z., Gao, B., & Wang, H. (2014) · Hepatology · doi:10.1002/hep.27406 · Cited by 1,261
Self-citationPrevalence of the metabolic syndrome and overweight among adults in China
Gu, D., Reynolds, K., Wu, X., Chen, J., Duan, X., Reynolds, R. F., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66375-1 · Cited by 917
Self-citationGlobal Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Lonardo, A., Nascimbeni, F., Mantovani, A., & Targher, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.021 · Cited by 736
Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China
Bragg, F., Holmes, M. V., Iona, A., Guo, Y., Du, H., Chen, Y., Bian, Z., Yang, L., Herrington, W., Bennett, D., et al. (2017) · JAMA · doi:10.1001/jama.2016.19720 · Cited by 497
Self-citationToward a more accurate estimate of the prevalence of hepatitis C in the United States
Edlin, B. R., Eckhardt, B. J., Shu, M. A., Holmberg, S. D., & Swan, T. (2015) · Hepatology · doi:10.1002/hep.27978 · Cited by 433
Kowdley, K. V., Wang, C. C., Welch, S., Roberts, H., & Brosgart, C. L. (2012) · Hepatology · doi:10.1002/hep.24804 · Cited by 400
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2015) · Hepatology · doi:10.1002/hep.27678 · Cited by 354
The global burden of liver disease: a challenge for methods and for public health
Byass, P. (2014) · BMC Medicine · doi:10.1186/s12916-014-0159-5 · Cited by 321
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)
Hou, J., Wang, G., Wang, F., Cheng, J., Ren, H., Zhuang, H., Sun, J., Li, L., Li, J., Meng, Q., et al. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00019 · Cited by 270
Self-citationInternational incidence and mortality trends of liver cancer: a global profile
Wong, M. C. S., Jiang, J. Y., Goggins, W. B., Liang, M., Fang, Y., Fung, F. D. H., Leung, C., Wang, H. H. X., Wong, G. L. H., Wong, V. W. S., et al. (2017) · Scientific Reports · doi:10.1038/srep45846 · Cited by 255
Self-citationEpidemiology of alcoholic and nonalcoholic fatty liver disease in China
Fan, J. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12036 · Cited by 247
HCV direct‐acting antiviral agents: the best interferon‐free combinations
Schinazi, R., Halfon, P., Marcellin, P., & Asselah, T. (2014) · Liver International · doi:10.1111/liv.12423 · Cited by 230
Feng, R.-N., Du, S.-S., Wang, C., Li, Y.-C., Liu, L.-Y., Guo, F.-C., & Sun, C.-H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17932 · Cited by 226
The guideline of prevention and treatment for chronic hepatitis B: a 2015 update
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, C. M. A. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/j.issn.1001-5256.2015.12.002 · Cited by 216
SCImago Journal & Country Rank
Krajna, T. (2008) · University of Zagreb University Computing Centre (SRCE) · Cited by 211
Li, Z., Xue, J., Chen, P., Chen, L., Yan, S., & Liu, L. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12428 · Cited by 202
Alcohol and alcohol-related harm in China: policy changes needed
Tang, Y.-L., Xiang, X.-J., Wang, X.-Y., Cubells, J. F., Babor, T. F., & Hao, W. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.107318 · Cited by 193
Alcoholic Liver Disease in Asia, Europe, and North America
Liangpunsakul, S., Haber, P., & McCaughan, G. W. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.043 · Cited by 180
Ji, Cheng, Ye, et al. (2013) · 生物医学与环境科学:英文版 · Cited by 162
Nishioji, K., Sumida, Y., Kamaguchi, M., Mochizuki, N., Kobayashi, M., Nishimura, T., Yamaguchi, K., & Itoh, Y. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0948-9 · Cited by 160
The Difference in Nutrient Intakes between Chinese and Mediterranean, Japanese and American Diets
Zhang, R., Wang, Z., Fei, Y., Zhou, B., Zheng, S., Wang, L., Huang, L.-C., Jiang, S. S., Liu, Z., Jiang, J., et al. (2015) · Nutrients · doi:10.3390/nu7064661 · Cited by 124
Self-citationHerbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Medina-Caliz, I., Garcia-Cortes, M., Gonzalez-Jimenez, A., Cabello, M. R., Robles-Diaz, M., Sanabria-Cabrera, J., Sanjuan-Jimenez, R., Ortega-Alonso, A., García-Muñoz, B., Moreno, I., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.051 · Cited by 111
Prevalence of fatty liver disease and the economy in China: A systematic review
Zhu, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i18.5695 · Cited by 77
The Burden of Illness for Patients with Viral Hepatitis C: Evidence from a National Survey in Japan
Liu, G. G., DiBonaventura, M., Yuan, Y., Wagner, J.-S., L'Italien, G. J., Langley, P. C., & Kamae, I. (2012) · Value in Health · doi:10.1016/j.jval.2011.11.012 · Cited by 67
Time Trends in Fast Food Consumption and Its Association with Obesity among Children in China
Xue, H., Wu, Y. F., Wang, X., & Wang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151141 · Cited by 62
The Japanese Society of Gastroenterology
范馨月, & 黄亚明 (2017) · 中华内科杂志 · doi:10.3760/cma.j.issn.0578-1426.2017.08.102 · Cited by 58
Sun, Y., Wang, Y., Li, M., Cheng, K., Zhao, X., Zheng, Y., Liu, Y., Lei, S., & Wang, L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020490 · Cited by 50
Self-citationCancer drug development in China: recent advances and future challenges
Wu, Y.-L. L. C., Zhang, H., & Yang, Y. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.005 · Cited by 28
Research works printed but not linked: 8
- Ohishi, 2009, Current treatment for chronic hepatitis B in Japan, Clin J Gastroenterol, 2, 325, 10.1007/s12328-009-0100-1 · doi:10.1007/s12328-009-0100-1
- Rao, 2014, Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection, J Gastroenterol Hepatol, 29, 545, 10.1111/jgh.12398 · doi:10.1111/jgh.12398
- Goyal, 2016, Cost-effectiveness of peg-interferon, interferon and oral nucleoside analogues in the treatment of chronic hepatitis B and D infections in China, Clin Drug Invest, 36, 637, 10.1007/s40261-016-0409-8 · doi:10.1007/s40261-016-0409-8
- 2016, Guideline of prevention and treatment for hepatitis C (2015 Update), J Pract Hepatol, 19, S9
- Lu, 2018, Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China, PLoS ONE, 13
- Chang, 2018, Analysis and suggestions on the situation of hepatitis C treatment and related medical insurance compensation mechanism in China, China Pharm, 29, 151
- Ellis, 2018, Biotech booms in China, Nature, 553, S19, 10.1038/d41586-018-00542-3 · doi:10.1038/d41586-018-00542-3
- Grueber, 2014, 2014 global R&D funding forecast, R&D Magazine, 16, 1
Cited by
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Self-citationSun, D.-Q., Jin, Y., Wang, T.-Y., Zheng, K. I., Rios, R. S., Zhang, H.-Y., Targher, G., Byrne, C. D., Yuan, W.-J., & Zheng, M.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154433 · Cited by 308
Zhang, L.-F., Wang, X.-H., Zhang, C.-L., Lee, J., Duan, B.-W., Xing, L., Li, L., Oh, Y.-K., & Jiang, H.-L. (2022) · ACS Nano · doi:10.1021/acsnano.2c03858 · Cited by 92
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Self-citation
Metadata
- Authors
- Xiao, J., Wang, F., Wong, N.-K., He, J., Zhang, R., Sun, R., Xu, Y., Liu, Y., Li, W., Koike, K., He, W., You, H., Miao, Y., Liu, X., Meng, M., Gao, B., Wang, H., & Li, C.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 71
- Issue
- 1
- Pages
- 212-221
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2922188864
- Cited by
- 547
- References
- 36
- FWCI
- 38.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.